Cargando…

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors

OBJECTIVE: To develop and validate a nomogram model for predicting chronic ocular graft-versus-host disease (coGVHD) in patients after allogenic haematopoietic stem cell transplantation (allo-HSCT). METHODS: This study included 61 patients who survived at least 100 days after allo-HSCT. Risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wen-hui, You, Li-li, Huang, Ke-zhi, Li, Zi-jing, Hu, Yu-xin, Gu, Si-min, Li, Yi-qing, Xiao, Jian-hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869507/ https://www.ncbi.nlm.nih.gov/pubmed/36690959 http://dx.doi.org/10.1186/s12886-022-02745-9

Ejemplares similares

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients
por: Hossain, Mohammad S., et al.
Publicado: (2017)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

Pathophysiology of GvHD and Other HSCT-Related Major Complications
por: Ghimire, Sakhila, et al.
Publicado: (2017)

Early myeloid-derived suppressor cells (HLA-DR(−)/(low)CD33(+)CD16(−)) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT
por: Wang, Ke, et al.
Publicado: (2019)

Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
por: Xuan, Li, et al.
Publicado: (2016)

Family caregivers’ support needs during allo-HSCT—a longitudinal study
por: Kisch, Annika M., et al.
Publicado: (2020)

Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
por: Lange, Andrzej, et al.
Publicado: (2021)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

Blockade of Vascular Endothelial Growth Factor (VEGF) Aggravates the Severity of Acute Graft-versus-host Disease (GVHD) after Experimental Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
por: Kim, Ai-Ran, et al.
Publicado: (2011)

Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Oral Cancer in HSCT Pediatric Patients Arising on GVHD: A Comprehensive Review
por: Cantile, Tiziana, et al.
Publicado: (2022)

TKIs combined with chemotherapy followed by allo-HSCT in Philadelphia chromosome-positive myelodysplastic syndrome: A case report and literature review
por: Qi, Shasha, et al.
Publicado: (2022)

Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐HSCT
por: Meng, Lijuan, et al.
Publicado: (2018)

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis
por: Zhu, Yangmin, et al.
Publicado: (2020)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
por: Wang, Luxiang, et al.
Publicado: (2023)

CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
por: Wen, Shupeng, et al.
Publicado: (2018)

Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
por: Ren, Jinhua, et al.
Publicado: (2023)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH
por: Du, Zhi zhuo, et al.
Publicado: (2022)

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2020)

A Nationwide Study of GATA2 Deficiency in Norway—the Majority of Patients Have Undergone Allo-HSCT
por: Jørgensen, Silje F., et al.
Publicado: (2021)

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA
por: Cerezo-Martin, J. M., et al.
Publicado: (2022)

Clinical study of late-onset hemorrhagic cystitis after allo-HSCT without in vitro T-cell depletion
por: Yuan, Hailong, et al.
Publicado: (2022)

Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
por: Xu, Qianwen, et al.
Publicado: (2023)

Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients
por: Han, Lijie, et al.
Publicado: (2018)

Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT
por: Luo, Rongmu, et al.
Publicado: (2022)

Abnormalities by Multicolor Flow Cytometry for Detection of Minimal Residual Disease in Recipients of Allo-HSCT Originating from Donors: A Cohort Study
por: Wang, Hui, et al.
Publicado: (2023)

Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients
por: Skaarud, K. J., et al.
Publicado: (2019)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis
por: Yang, Apeng, et al.
Publicado: (2019)

Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2021)

Pre-transplant Rehabilitation to Decrease the Post-transplant Length of Stay for Hematological Malignancy Patients Undergoing Allo-HSCT
por: Matsugaki, Ryutaro, et al.
Publicado: (2021)

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Tafazoli, Ali, et al.
Publicado: (2019)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uj5quh3apbhpfr2cpg9r1973b4